Vaccination schedule of the spanish association of paediatrics: Recommendations 2010;Calendario de vacunaciones de la Asociación Española de Pediatría: recomendaciones 2010

Anales de Pediatria

Volumn 72, Issue 6, 2010, Pages

  Bermúdez, J Marés ^a   Arbolave, D Van Esso ^a   Fernández, J Arístegui ^a   Contreras, J Ruiz ^a   Hachero, J González ^a   Moína, M Merino ^a   Corrales, F Barrio ^a   García, F J Álvarez ^a   Ortega, M J Cilleruelo ^a   Del Castillo, L Ortigosa ^a   Pérez, D Moreno ^a  

^a Hospital Clínico   (Spain)

Author keywords

Catch up immunization schedules; Immunization schedule; Vaccine preventable diseases; Vaccines

Indexed keywords

CHICKENPOX VACCINE; HEPATITIS A VACCINE; INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE; ROTAVIRUS VACCINE;

CHICKENPOX; DISEASE ASSOCIATION; EPIDEMIOLOGICAL DATA; FUNDING; HEALTH CARE SYSTEM; HEPATITIS; HEPATITIS A; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; INFLUENZA; MEDICAL SOCIETY; NONHUMAN; PEDIATRICS; PNEUMOCOCCAL INFECTION; PUBLIC HEALTH SERVICE; REVIEW; ROTAVIRUS; ROTAVIRUS INFECTION; SPAIN; VACCINATION; WART VIRUS;

EID: 77953232602     PISSN: 16954033     EISSN: 16959531     Source Type: Journal    
DOI: 10.1016/j.anpedi.2010.02.009     Document Type: Article

References (125)

1. E. Bernaola, F. Gimnez, M. Baca, F. De Juan, J. Dez, and M. Garcs Calendario Vacunal de la Asociacin Espaola de Pediatra: recomendaciones de 2009 An Pediatr (Barc) 70 2009 72 82
2. Centers for Disease Control and Prevention Recommended immunization schedules for persons aged 0 through 18 years United States, 2010 MMWR Morb Mortal Wkly Rep 58 2010 51 52
3. Centers for Disease Control and Prevention Licensure of a Haemophilus influenzae Type b (Hib) vaccine (Hiberix) and updated recommendations for use of Hib vaccine MMWR Morb Mortal Wkly Rep 58 36 2009 1008 1009
4. A. Fenoll, J.J. Granizo, L. Aguilar, M.J. Gimnez, L. Aragoneses-Fenoll, and G. Hanquet Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007 J Clin Microbiol 47 2009 1012 1020
5. C. Muoz-Almagro, I. Jordan, A. Gene, C. Latorre, J.J. Garca-Garca, and R. Pallars Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine Clin Infect Dis 46 2008 174 182
6. Fenoll A, Gimnez MJ, Vicioso MD, Aguilar L, Robledo O, Granizo JJ, et al. Trends of the ten most prevalent pneumococcal serotype among invasive isolates from children in the last 12 years in Spain. 6th World Congress of the World Society for Pediatric Infectious Diseases (WSPID). November 18-22, 2009, Buenos Aires Argentina. Book of Abstracts. Pag 285.
7. Fenoll A, Gimnez MJ, Vicioso MD, Aguilar L, Robledo O, Granizo JJ. Trends of prevalent pneumococcal serotypes among adult invasive isolates pre- and post-licensure of 7-PCV for children in Spain. 6th World Congress of the World Society for Pediatric Infectious Diseases (WSPID). November 18-22, 2009, Buenos Aires Argentina. Book of Abstracts. Pag 78.
8. C. Ardanuy, F. Fubau, R. Pallares, L. Calatayud, M.A. Domnguez, and D. Rolo Epdemiology of invasive pneumococcal disease among adult patients in Barcelona before and after pediatric 7-valent pneumococcal vaccine introduction, 19972007 Clin Infect Dis 48 2009 57 64
9. A. Fenoll, I. Jado, D. Vicioso, S. Berrn, J.E. Yuste, and J. Casal Streptococcus pneumoniae in children in Spain: 19909 Acta Pediatrn Esp 435 2000 44S 50S
10. Ministerio de Sanidad y Consumo. Instituto de Salud Carlos III. Enfermedad invasora por Streptococcus pneumoniae: estudio de la incidencia de la enfermedad en menores de 5 aos. Agosto 2004.
11. Picazo J, Ruiz-Contreras J, Casado-Flores J, Giangaspro E, Castillo F, Hernndez San Pelayo T, et al. Invasive Streptococcus pneumoniae serotype distribution among hospitalized pediatric population in Madrid (May 2007-April 2008). 27th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID). Brussels, Belgium June 913, 2009.
12. E. Calbo, A. Daz, E. Caadel, J. Fbrega, S. Uriz, and M. Xercavins Invasive pneumococcal disease among children in a health district of Barcelona: early impact of pneumococcal conjugate vaccine Clin Microbiol Infect 12 2006 867 872
13. L. Salleras, A. Domnguez, P. Ciruela, C. Izquierdo, E. Navas, and N. Torner Changes in serotypes causing invasive pneumococcal disease (20052007 vs 19971999) in children under 2 years of age in a population with intermediate coverage of the 7-valent pneumococcal conjugated vaccine Clin Microbiol Infect 15 2009 997101
14. I. Obando, L.A. Arroyo, D. Snchez-Tatay, D. Tarrag, D. Moreno, and W.P. Hausdorff Molecular epidemiology of paediatric invasive pneumococcal disease in southern Spain after the introduction of heptavalent pneumococcal conjugate vaccine Clin Microbiol Infect 13 2007 347 349
15. W.P. Hausdorff The roles of pneumococcal serotypes 1 and 5 in paediatric invasive disease Vaccine 25 2007 2406 2412
16. M.G. Romney, M.W. Hull, R. Gustafson, J. Sandhu, S. Champagne, and T. Wong Large community outbreak of Streptococcus pneumoniae serotype 5 invasive infection in an impoverished, urban population Clin Infect Dis 47 2008 768 774
17. C. Muoz-Almagro, C. Esteva, M. Fernndez de Sevilla, L. Selva, A. Gene, and R. Pallars Emergence of invasive pneumococcal disease caused by multidrug-resistant serotype 19A among children in Barcelona J Infect 59 2009 75 82
18. Picazo J, Ruiz-Contreras J, Casado-Flores J, Negreira S, Castillo F, Hernndez Sampelayo T, et al. Serotype-specific clinical outcomes of invasive pneumococcal disease (IPD) among hospitalized pediatric population in Madrid (May 2007April 2008). 27th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID). Brussels, Belgium June 913, 2009.
19. Fenoll A, Aguilar L, Vicioso MD, Gimnez NJ, Robledo O, Granizo JJ, et al. Serotype 19A prevalence among Spanish Streptococcus pneumoniae invasive isolates (19972008) and its susceptibility to penicillin, cefotaxime and erythromycin. 6th World Congress of the World Society for Pediatric Infectious Diseases. November 1822, 2009, Buenos Aires Argentina. Book of Abstracts. Pag 77.
20. W.P. Hausdorff, D.R. Feikin, and K.P. Klugman Epidemiological differences among pneumococcal serotypes Lancet Infect Dis 5 2005 83 93
21. D.A. Spencer, S.M. Iqbal, A. Hasan, and L. Hamilton Empyema is still in UK children BMJ 332 2006 1333
22. L. Deiros, F. Baquero-Artigao, M.J. Garca-Miguel, N. Hernndez, P. Pea, and F. Del Castillo Derrame pleural paraneumnico: revisin de 11 aos An Pediatr (Barc) 64 2006 40 45
23. I. Obando, C. Muoz-Almagro, L.A. Arroyo, D. Tarrago, D. Snchez-Tatay, and D. Moreno-Prez Pediatric parapneumonic empiema, Spain Emerg Infect Dis 14 2008 1390 1397
24. A.B. Brueggemann, T.E. Peto, D.W. Crook, J.C. Butler, K.G. Kristinsson, and B.G. Spratt Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children J Infect Dis 190 2004 1203 1211
25. S. Rckinger, R. Von Kries, A. Siedler, and M. Van der Linden Association of serotype of Streptococcus pneumoniae with risk of severe fatal outcome Pediatr Infect Dis J 28 2009 118 122
26. J.M. Bender, K. Ampofo, K. Korgenski, J. Daly, T. Pavia a, and E.O. Mason Pneumococcal necrotizing pneumonia in Utah: does serotype matter? Clin Infect Dis 46 2008 1346 1352
27. C.G. Whitney Can vaccines control resistance? The example of pneumococcal conjugate vaccine. Infect Dis Clin Pract 14 2006 S24 S30
28. R. Dagan, and K. Klugman Impact of conjugate pneumococcal vaccines on antibiotic resistance Lancet Infect Dis 8 2008 785 795
29. F. Ghaffar, T. Barton, J. Lozano, L.S. Muniz, P. Hicks, and V. Gan Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumonia in the first two years of life Clin Infect Dis 39 2004 930 938
30. S.I. Pelton, A.M. Loughlin, and C.D. Marchant Seven valent pneumococcal conjugate vaccine immunization in two Boston communities. Changes in serotypes and antimicrobial susceptibility among Streptococcus pneumoniae isolates Pediatr Infect Dis J 23 2004 1015 1022
31. D.S. Stephens, S.M. Zughaier, C.G. Whitney, W.S. Baughman, L. Barker, and K. Gay Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment Lancet 365 2005 855 863
32. M.H. Kyaw, R. Lynfield, W. Schaffner, A.S. Craig, J. Hadler, and A. Reingold Effect of Introduction of the Pneumococcal Conjugate Vaccine on Drug-Resistant Streptococcus pneumoniae N Engl J Med 354 2006 1455 1463
33. Picazo JJ, Ruiz Contreras J, Casado-Flores J, Sanz F, Gutirrez A, Bouza E, et al. Genotypic characterization and antibiotic susceptibility of Streptococcus pneumoniae serotype 19 isolates in children in Madrid, 20072008 (Heracles study). 6th World Congress of the World Society for Pediatric Infectious Diseases (WSPID). November 1822, 2009, Buenos Aires Argentina. Book of Abstracts pag.51
34. R. Dagan, L. Givon, E. Leibovitz, D. Greenberg, and N. Porat Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population J Infect Dis 199 2009 776 785
35. M.R. Moore, R.E. Gertz, R.L. Woodbury, G.A. Barkoy-Gallagher, W. Schaffner, and C. Lexau Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005 J Infect Dis 197 2008 1016 1027
36. G.R. Siber, I.H. Chang, S. Baker, P. Fernsten, K.L. O′Brien, and M. Santosham Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies Vaccine 25 2007 3816 3826
37. World Health Organization Pneumococcal conjugate vaccines. Recommendations for production and control of pneumococcal conjugate vaccines World Health Organ Tech Rep Ser 927 2005 64 98 (annex 2)
38. T. Vesikari, J. Wysocki, B. Chevallier, A. Karvonen, C. Hanna, and J.P. Arsne Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenza protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine Pediatr Infect Dis J 28 2009 S66 S76
39. J. Wysocki, J.C. Tejedor, D. Grunet, R. Konior, J. Garca-Sicilia, and M. Knuf Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different Neisseria meningitidis serogroup C conjugate vaccines Pediatr Infect Dis J 28 2009 S77 S88
40. N. Bermal, L. Szenborn, A. Chrobot, E. Alberto, P. Lommel, and S. Gatchalian The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of the immunogenicity Pediatr Infect Dis J 28 2009 S89 S96
41. M. Knuf, L. Szenborn, M. Moro, C. Petit, N. Bernal, and L. Bernard Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) Pediatr Infect Dis 28 2009 S97 S108
42. B. Chevallier, T. Vesikari, J. Brzostek, M. Knuf, M. Bermal, and J. Arstegui Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines Pediatr Infect Dis J 28 2009 S109 S118
43. Kieninger DM, Keuper K, Steul K, Juergens C, Ahlers N, Baker S, et al. Safety and immunologic non-inferiority of a 13-valent pneumococcal conjugate vaccine compared to 7-valent pneumococcal conjugate vaccine given as a 4 dose series with routine vaccines in healthy infants and toddlers. Presented at the 48th Annual ICAAC/IDSA Meeting, October 2528, 2008, Washington DC.
44. Gadziowski J, Daniels ED, Giardina P, Patterson S, Tansey S, Emini EA, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine with and without polysorbate 80 in healthy infants given at 2, 3, 4 and 12 months of age. Presented at the 27th Annual Meeting of the European Society for Paediatric Infectious Disease (ESPID), June 913, 2009, Brussels, Belgium.
45. Diez-Domingo J, Gurtman A, Bernaola E, Gimnez-Snchez F, Martinn-Torres F, Pineda-Solas V, et al. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in healthy infants receiving routine vaccinations in Spain. Presented at the 27th Annual Meeting of the European Society for Paediatric Infectious Disease (ESPID), June 913, 2009, Brussels, Belgium.
46. Esposito S, Tansey S, Thompson A, Ferrera G, Maida A, Bona G, et al. Safety and immunologic non-inferiority of 13-valent pneumococcal conjugate vaccine given as a 3-dose series with routine vaccines in healthy children in Italy. Presented at the 27th Annual Meeting of the European Society for Paediatric Infectious Disease (ESPID), June 913, 2009, Brussels, Belgium.
47. Martinon-Torres F, Gimenez-Sanchez F, Gurtman A, Bernaola E, Dez-Domingo J, Carmona A et al. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in healthy infants receiving routine vaccinations in Spain. Presented at the 27th Annual Meeting of the European Society for Paediatric Infectious Disease (ESPID), June 913, 2009, Brussels, Belgium.
48. Grimprel E, Laudat F, Baker SA, Sidhu MS, Sekaran C, Gruber WC, et al. Immunogenicity of a 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccination to healthy children in France. Presented at the 27th Annual Meeting of the European Society for Paediatric Infectious Disease (ESPID), June 913, 2009, Brussels, Belgium.
49. R.C. Kohberger, J. Joniken, and G.R. Siber Establishing immune correlates of protection G.R. Siber, K.P. Klugman, P.H. Mkel, Pneumococcal vaccines. The impact of conjugate vaccines 2008 ASM Press Washington DC 339 349
50. J.T. Jokinen, H. Ahman, T.M. Kilpi, H. Mkel, and H. Kyhty Concentration of anti-pneumococcal antibodies as a serological correlate of protection: an application to acute otitis media J Infect Dis 190 2004 545 550
51. G.L. Rodgers, A. Arguedas, R. Cohen, and R. Dagan Global serotype distribution among Streptococcus pneumoniae isolates causing otitis media in children: potential implications for pneumococcal conjugate vaccines Vaccine 27 2009 3802 3810
52. M.E. Pichichero, and J.R. Casey Emergence of multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugante vaccine as an otopathogen in children JAMA 298 2007 1772 1778
53. M.C. McEllistren, J.M. Adams, K. Patel, A.B. Mendelson, S.L. Kaplan, and J.S. Bradley Acute otitis media due to penicillin-nonsusceptible Streptococcus pneumoniae before and after the introduction of the pneumococcal conjugate vaccine Clin Infect Dis 40 2005 1738 1744
54. R. Prymula, P. Peters, V. Chrobok, P. Kriz, E. Novakova, and E. Kaliskova Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused both Streptococcus pneumoniae and non-typeable Hemophilus influenzae: a randomized double-blind efficacy study Lancet 367 2006 740 748
55. S. Esposito, S. Bosis, R. Cavagna, N. Faelli, E. Begliatti, and P. Marchisio Characteristics of Streptococcus pneumoniae and atypical bacterial infections in children 25 years of age with community-acquired pneumonia Clin Infect Dis 35 2002 1345 1352
56. I.C. Michelow, K. Olsen, J. Lozano, N.K. Rollins, L.B. Duffy, and T. Ziegler Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children Pediatrics 113 2004 701 707
57. V.P. Hausdorff, and R. Dagan Serotypes and pathogens in paediatric pneumonia Vaccine 2008 10.1016/j.vaccine.2008.05.033 (Pubitemid 351893199)
58. M. Pava, A. Blanco, C.G. Nobile, P. Marinelli, and I.F. Angelillo Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-analysis Pediatrics 123 2009 e1103 e1110
59. Centers for Disease Control and Prevention Direct and indirect effects of routine vaccination of children with 7-valent pneumococccal conjugate vaccine on incidence of invasive pneumococcal disease. United States, 19982003 MMWR 54 2005 893 897
60. G. Bjornson, D.W. Scheifele, J. Bettinger, D.M. Patrick, L. Gustafson, and P. Daly Effectiveness of pneumococcal conjugate vaccines in Greater Vancouver, Canada: 20042005 Pediatr Infect Dis J 26 2007 540 542
61. J.P. Metlay, N.O. Fishman, M. Joffe, and P.H. Edelstein Impact of pediatric vaccination with pneumococcal conjugate vaccine on the risk of bacteremic pneumococcal pneumonia in adults Vaccine 24 2006 468 475
62. K.A. Poehling, T.R. Talbot, M.R. Griffin, A.S. Craig, C.G. Whitney, and E. Zell Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine JAMA 295 2006 1668 1674
63. R. Dagan, N. Givon-Lavi, O. Zamir, and D. Fraser Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers Pediatr Infect Dis J 22 2003 532 539
64. F.M. Russell, A. Balloch, M.L.K. Tang, J.R. Carapetis, P. Licciardi, and J. Nelson Immunogenicity following one, two or three doses of the 7-valent pneumococcal conjugate vaccine Vaccine 27 2009 5685 5691
65. J.F. Seward, B.M. Watson, C.L. Peterson, L. Mascola, J.W. Pelosi, and J.X. Zhang Varicella Disease After Introduction of Varicella Vaccine in the United States, 19952000 JAMA 287 2002 606 611
66. J.F. Seward, M. Marin, and M. Vzquez Varicella vaccine effectiveness in the US vaccination program A review. J Infect Dis 197 2008 S82 S89
67. H.Q. Nguyen, A.O. Jumaan, and J.F. Seward Decline in mortality due to varicella after implementation of varicella vaccination in the United States N Engl J Med 352 2005 450 458
68. M.A. Reynolds, B.M. Watson, K.K. Plott-Adams, A.O. Jumaan, K. Galil, and T.J. Maupin Epidemiology of varicella hospitalizations in the United States, 1995-2005 J Infect Dis 197 2008 S120 S126
69. R. Patel, H.J. Binns, and S.T. Shulman Reduction in pediatric hospitalizations for varicella-related invasive group A streptococcal infections in the varicella vaccine era J Pediatr 144 2004 68 74
70. M.S. Dworkin, C.E. Jennings, J. Roth-Thomas, J.E. Lang, C. Stukenberg, and J.R. Lumpkin An outbreak of varicella among children attending preschool and elementary school in Illinois Clin Infect Dis 35 2002 102 104
71. K. Galil, B. Lee, T. Strine, C. Carraher, A.L. Baughman, and M. Eaton Outbreak of varicella at a day-care center despite vaccination N Engl J Med 347 2002 1909 1915
72. B.D. Tugwell, L.E. Lee, H. Gillette, E.M. Lorber, K. Hedberg, and P.R. Cieslak Chickenpox outbreak in highly vaccinated school population Pediatrics 113 2004 455 459
73. Outbreak of varicella among vaccinated children Michigan. 2003 MMWR Morb Mortal Wkly Rep 53 2004 389 392
74. M. Vazquez, P.S. LaRussa, A.A. Gershon, L.M. Niccolai, C.E. Muehlbein, and S.P. Steinberg Effectiveness over time of varicella vaccine JAMA 291 2004 851 855
75. O. Bayer, U. Heininger, C. Heiligenstzer, and R. Von Kries Metaanalysis of vaccine effectiveness in varicella outbreaks Vaccine 25 2007 6655 6660
76. S.S. Chaves, P. Gargiullo, J.X. Zhang, R. Civen, D. Guris, and L. Mascota Loss of vaccine-induced immunity to varicella vaccine over time N Engl J Med 356 2007 1121 1129
77. M. Marin, H.Q. Nguyen, J. Keen, A.O. Jumaan, P.M. Mellen, and E.B. Hayes Importance of Catch-up vaccination: experience from a varicella outbreak, Maine, 20022003 Pediatrics 115 2005 900 905
78. M.B. Haddad, M.B. Hill, A.T. Pavia, C.E. Green, A.O. Jumaan, and A.K. De Vaccine effectiveness during a varicella outbreak among schoolchildren: Utah, 20022003 Pediatrics 115 2005 1488 1493
79. S.S. Chaves, J. Zhang, R. Civen, B.M. Watson, T. Carbajal, and D. Perella Varicella disease among vaccinated persons. Clinical and epidemiological characteristics, 19972005 J Infect Dis 197 2008 S127 S131
80. B. Kuter, H. Matthews, H. Shinefield, S. Black, P. Dennehy, and B. Watson Ten year follow-up of healthy children who received one or two injections of varicella vaccine Pediatr Infect Dis J 23 2004 132 137
81. M. Marin, D. Guris, S.S. Chaves, S. Schmid, and J.F. Seward Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep 56 2007 1 40
82. B. Watson Humoral and cell-mediated immune responses in children and adults after 1 and 2 doses of varicella vaccine J Infect Dis 197 2008 S143 S146
83. W.J. Edmunds, and M. Brisson The effect of vaccinationon in the Epidemiology of varicella zoster J Infect 2002 211 219
84. Centers for Disease Control and Prevention Prevention of rotavirus gastroenteritis among infants children: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR 58 2009 1 25
85. F.A. Moraga, and J. Mars Vacunacin E. Roman, Actualizacin en la infeccin por rotavirus 2009 Undergraf, SL Madrid 41 65
86. E. Muoz, J.R. Bretn, A. Ros, A. Rodrguez, B. Casado, and R. Hernndez Gastroenteritis aguda infecciosa en urgencias de un hospital urbano An Pediatr (Barc) 68 2008 432 438
87. A. Lopez de Andrs, R. Jimnez-Garca, P. Carrasco-Garrido, A. Alvaro-Meca, P.G. Galarza, and A. Gil de Miguel Hospitalizations associated with rotavirus gastroenteritis in Spain BMC Public Health 8 2008 109
88. F.J. Luquero, J.M. Eiros, A.P. Rubio, M.R. Bachiller, J.J. Castrodeza, and R. Ortiz de Lejarazu Gastroenteritis by rotavirus in Spanish children. Analysis of the disease burden Eur J Pediatr 167 2008 549 555
89. J. Forster, A. Guarino, N. Parez, F. Moraga, E. Romn, O. Mory and the Rotavirus Study Group Hospital-based surveillance to estimate the burden of rotavirus gastroenteritis among european children younger than 5 years of age Pediatrics 123 2009 e393 e400
90. F. Martinn, M. Bouzn-Alejandro, L. Lpez-Sousa, L. Redondo-Collazo, S. Almeida-Agudn, and C. Astorgano-Fernndez An estimation of indirect costs caused by acute rotavirus gastroenteritis in a Galician area, Spain Eur J Pediat 167 2008 337 339
91. T. Vesikari, A. Karvonen, V. Prymula, V. Schuster, J.C. Tejedor, and R. Cohen Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised double-blind controlled study Lancet 370 2007 1757 1763
92. G.M. Ruiz-Palacios, I. Prez-Shael, R. Velsquez, H. Abate, T. Breuer, and S.A. Costa-Clemens Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis N Eng J Med 354 2006 11 22
93. B. De Vos, H.H. Han, A. Bouckenooghe, S. Debrus, P. Gillard, and R. Ward Live attenuated human rotavirus vaccine, RIX4414, provides clinical protection in infants against rotavirus strains with and without shared G and P genotypes: integrated analysis of randomized controlled trials Pediatr Infect Dis J 28 2009 261 266
94. T. Vesikari, D.O. Matson, P. Dennehy, P. Van Damme, M. Santosham, and Z. Rodrguez Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine N Eng J Med 354 2006 23 33 (Pubitemid 43048948)
95. D.I. Bernstein Rotavirus overview Pediatr Infect Dis J 28 2009 S50 S53
96. Omeaca F, Sarlangue J, Wysocki J, Nogueira M, Suryakiran PV, Smolenov IV, et al. Immunogenicity of a rotavirus vaccine (Rotarix®) in European pre-term infants with different gestational age. 27th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID). Brussels, Belgium 913 June, 2009. Abstract 645, Poster 1001.
97. M.G. Goveia, Z.M. Rodrguez, M.U. Dallas, R.F. Itzler, J.W. Boslego, and P.M. Heaton Safety and efficacy of pentavalent humans-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants Pediatr Infect Dis J 26 2007 1099 1104
98. Centers for Disease Control and Prevention Reduction in rotavirus after vaccine introduction United States, 20002009 MMWR 58 2009 1146 1149
99. T. Vesikai, P. Van Damme, C. Giaquinto, J. Gray, J. Mrukowicz, and R. Dagan Recomendaciones basadas en la evidencia de la Sociedad Europea de Enfermedades Infecciosas Peditricas y la Sociedad Europea de Gastroenterologa, Hepatologa y Nutricin peditrica para la vacunacin frente al rotavirus en Europa J Pediatr Gastroenterol Nutr 46 2008 1 15 (Ed. Esp)
100. World Health Organization Rotavirus vaccines: an update Wkly Epidemiol Rec 84 2009 533 538
101. Pachn I, Martinez MV, Suarez B, Snchez-Fouquier A, Salmern F, Soler M, et al. Situacin epidemiolgica de la gastroenteritis producida por rotavirus. Recomendaciones de la vacunacin frente al rotavirus. Documento enviado a la Ponencia de Programa y registro de vacunaciones, Junio 2006. Madrid: Ministerio de Sanidad y Consumo.
102. T. Agorastos, K. Chatzigeorgiou, J.M. Brotherton, and S.M. Garland Safety of human papillomavirus (HPV) vaccines: a review of international experience so far Vaccine 27 2009 7270 7281
103. B.A. Slade, L. Leidel, C. Vellozzi, E.J. Woo, W. Hua, and A. Sutherland Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine JAMA 302 2009 750 757
104. M.M. Braun, P.A. Patriarca, and S.S. Ellenberg Syncope after immunization Arch Pediatr Adolesc Med 151 1997 255 259
105. J.P. Buttery, S. Madin, N.W. Crawford, S. Elia, S. La Vincente, and S. Hanieh Mass Psychogenic response to human papillomavirus vaccination Med J Aust 189 2008 261 262
106. S.L. Block, D.R. Brown, A. Chatterjee, M.A. Gold, H.L. Sings, and A. Meilbohm Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (type 6, 11, 16 and 18) L1 virus-like particle vaccine Pediatr Infect Dis J 29 2010 95 101
107. A. Dana, K.M. Buchanan, M.A. Goss, M.M. Seminak, K.E. Shields, and S. Korn Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine Obstet Gynecol 114 2009 1170 1178
108. T. Callrus, H. Svanstrn, N.M. Nielsen, S. Poulsen, P. Valentiner-Brandth, and A. Hviid Human papillomavirus immunization of adolescent girls and anticipated reporting of immune-mediated adverse events Vaccine 27 2009 2954 2958
109. American Academy of Pediatrics Policy statement. Recommendations for the prevention and treatment of influenza in children, 20092010 Pediatrics 124 2009 1216 1226
110. Recomendaciones del Comit Asesor de Vacunas. Vacunacin antigripal estacional, campaa 2009-2010. http://www.vacunasaep.org/gripe-2009-2010.htm
111. A.E. Fiore, D.K. Shay, K. Broker, J.K. Iskander, T.M. Uyeki, and G. Mootrey Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009 MMWR Recomm Rep 58 2009 1 52
112. Consejo Interterritorial del Sistema Nacional de Salud. Campaa de vacunacin frente al nuevo virus gripal pandmico H1N1. Recomendaciones oficiales (Versin 5: 21 de diciembre de 2009). http://www.aemps.es/actividad/documentos/ infoInteres/docs/campanaVacunacion-H1N1-recomenOficiales.pdf.
113. Centers for Disease Control and Prevention. H1N1 flu. Vaccine safety. http://www.cdc.gov/h1n1flu/vaccination/vaccine-safety.htm.
114. World Health Organization. Safety of pandemic (H1N1) 2009 vaccines. http://www.who.int/csr/disease/swineflu/frequently-asked-questions/ vaccine-preparedness/safety-approval/en/index.html.
115. Centers for Disease Control and Prevention Safety of influenza A (H1N1) 2009 monovalent vaccines United States, October 1November 24, 2009 MMWR 58 2009 1351 1356
116. S.F. Liang, H.Q. Wang, J.Z. Wang, H.H. Fang, J. Wu, and F.C. Zhu Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double blind, randomised, placebo controlled-trial Lancet 2009 10.1016/S0140-6736(09)62003-1
117. Z. Vajo, F. Tamas, L. Sinka, and I. Jankovics Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 200910 influenza season: a multicentre, randomised controlled trial Lancet 2009 10.1016/S0140-6736(09)62039-0
118. R.L. Atmar, and W.A. Keitel Adjuvants for pandemic influenza vaccines Curr Top Microbiol Immunol 333 2009 323 324
119. K.G. Nicholson, A.E. Colegate, A. Podda, I. Stephenson, J. Wood, and E. Ypma Safety and antigenicity of non-adjuvanted and MF59-adjuvanted vaccine: a randomized trial of two potential vaccines against H5N1 influenza Lancet 357 2001 1937 1943
120. A. Podda The adjuvanted influenza vaccines with novel adjuvants: experience with the M59-adjuvanted vaccine Vaccine 19 2001 2673 2680
121. M. Pellegrini, U. Nicolay, K. Lindert, N. Groth, and G. Della Cioppa MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database Vaccine 27 2009 6959 6965
122. Centers for Disease Control and Prevention. Catch-up Immunization Schedule for Persons Aged 4 Months Through 18 Years Who Start Late or Who Are More Than 1 Month Behind. Disponible en: http://www.cdc.gov/vaccines/recs/ schedules/downloads/child/2010/10-catchup-schedule-pr.pdf.
123. The Australian Immunisation Handbook 9th Edition 2008. Catch-up-updated July 2009. Disponible en: http://www.immunise.health.gov.au/internet/immunise/ publishing.nsf/Content/handbook-catchup.
124. D. Van Esso, J. Mars, J. de la Flor, and J.M. Casanovas Vacunas para enfermera peditrica de atencin primaria 2009 Ed Runiping Barcelona
125. Corretger JM, Baraibar R. Nios no vacunados: pautas aceleradas. En: Vacunas en el nio. De la teora a la prctica. En: Arstegui J. editore. Junta de Andaluca. Consejera de Salud. Sevilla 2006; 80817.